Empowered Patient Podcast

Mike Pattwell, principal business advisor at Edifecs and Chair of the WEDI payment models work group, emphasizes the pandemic's impact on moving away from the fee-for-service model towards a value-based care model. Improving the administration of healthcare requires automation, new workflow solutions, and better data exchange to improve patient health. He mentions three organizations, including CMMI, WEDI, and CAQH, working towards creating interoperability and seamless communication between payers and providers.

Mike explains, "We've been around for 26 years, and we've been developing solutions to help our clients, mostly payers and providers, and health systems, to operationalize and automate workflows to improve the administration side of healthcare so that they can focus on doing what they do well, which is taking care of members and patients."

"Starting at the top, it would be The Center for Medicare and Medicaid Innovation (CMS) and the innovation center called CMMI. They're paving the future of healthcare for both payers and providers. They're supported by many other organizations. I'll briefly discuss three that I'm directly involved with and I believe are helping to develop and evolve healthcare. I call these three organizations "silent superheroes." They are the invisible organizations doing the hard work of creating interoperability and seamless automation between payers and providers. For decades, they've been enabling the future of healthcare."

#Edifecs #HealthInnovation #DIgitalTransformation #DigitalHealth #SDOH #Equity #HealthcareIT

edifecs.com

Listen to the podcast here

Mike Pattwell, principal business advisor at Edifecs and Chair of the WEDI payment models work group, emphasizes the pandemic's impact on moving away from the fee-for-service model towards a value-based care model. Improving the administration of healthcare requires automation, new workflow solutions, and better data exchange to improve patient health. He mentions three organizations, including CMMI, WEDI, and CAQH, working towards creating interoperability and seamless communication between payers and providers.

Mike explains, "We've been around for 26 years, and we've been developing solutions to help our clients, mostly payers and providers, and health systems, to operationalize and automate workflows to improve the administration side of healthcare so that they can focus on doing what they do well, which is taking care of members and patients."

"Starting at the top, it would be The Center for Medicare and Medicaid Innovation (CMS) and the innovation center called CMMI. They're paving the future of healthcare for both payers and providers. They're supported by many other organizations. I'll briefly discuss three that I'm directly involved with and I believe are helping to develop and evolve healthcare. I call these three organizations "silent superheroes." They are the invisible organizations doing the hard work of creating interoperability and seamless automation between payers and providers. For decades, they've been enabling the future of healthcare."

#Edifecs #HealthInnovation #DIgitalTransformation #DigitalHealth #SDOH #Equity #HealthcareIT

edifecs.com

Download the transcript here

Tim Moran, President and CEO of Avertix, discusses the company's mission to revolutionize how heart attack survivors are cared for and supported. Targeting patients who have had one prior heart attack or instance of a prior acute coronary syndrome, this first-of-its-kind technology is implanted in patients to monitor for the onset of another heart attack. The device notifies the patient in real-time so they can seek care and minimize the effects of the attack. Work is underway for providing cloud connectivity to the device, allowing data to be shared with physicians and family members.

Tim explains, "So in our study, patients that had The Guardian product implanted, we were able to reduce their time to care from the onset of symptoms by almost eight times. So we got the time down on average to 1.6 hours from the onset of symptoms where they arrived at an emergency room and then ultimately could have therapeutic intervention like a stent put in, which ultimately would reperfuse them and get blood flowing again. So, it's a significant reduction in time to care."

"The other thing that was interesting is we found during our study that our device can detect silent heart attacks. So, patients that don't have any symptoms at all, and in those instances during the study, we detected 42 silent events. The patient had no symptoms. Our Guardian device, what will do when it detects a heart attack, it's going to vibrate in the patient's chest. Then, it will also give them a secondary and tertiary warning on a small handheld device that'll give them an audio-visual alert."

"So, we're building a brand-new category in cardiology right now. We're speaking to our clinicians, cardiologists, and electrophysiologists on a daily basis about our new technology. And if you look at our FDA label, it's been approved for any patient that has had one prior heart attack or any instance of a prior acute coronary syndrome. So that's a very, very large patient population."

"From there, physicians can decide within the patient population they're treating. A patient with a prior heart attack may have other comorbidities such as diabetes, high blood pressure, or a smoker, which puts them at even an elevated risk for a second event. And these are the patients that we're targeting with The Guardian."

#Avertix #HeartAttack #TheGuardian #HeartAttackSurvivors #Implantable #Cardiologists #Electrophysiologists

avertix.com

Listen to the podcast here

Tim Moran, President and CEO of Avertix, discusses the company's mission to revolutionize how heart attack survivors are cared for and supported. Targeting patients who have had one prior heart attack or instance of a prior acute coronary syndrome, this first-of-its-kind technology is implanted in patients to monitor for the onset of another heart attack. The device notifies the patient in real-time so they can seek care and minimize the effects of the attack. Work is underway for providing cloud connectivity to the device, allowing data to be shared with physicians and family members.

Tim explains, "So in our study, patients that had The Guardian product implanted, we were able to reduce their time to care from the onset of symptoms by almost eight times. So we got the time down on average to 1.6 hours from the onset of symptoms where they arrived at an emergency room and then ultimately could have therapeutic intervention like a stent put in, which ultimately would reperfuse them and get blood flowing again. So, it's a significant reduction in time to care."

"The other thing that was interesting is we found during our study that our device can detect silent heart attacks. So, patients that don't have any symptoms at all, and in those instances during the study, we detected 42 silent events. The patient had no symptoms. Our Guardian device, what will do when it detects a heart attack, it's going to vibrate in the patient's chest. Then, it will also give them a secondary and tertiary warning on a small handheld device that'll give them an audio-visual alert."

"So, we're building a brand-new category in cardiology right now. We're speaking to our clinicians, cardiologists, and electrophysiologists on a daily basis about our new technology. And if you look at our FDA label, it's been approved for any patient that has had one prior heart attack or any instance of a prior acute coronary syndrome. So that's a very, very large patient population."

"From there, physicians can decide within the patient population they're treating. A patient with a prior heart attack may have other comorbidities such as diabetes, high blood pressure, or a smoker, which puts them at even an elevated risk for a second event. And these are the patients that we're targeting with The Guardian."

#Avertix #HeartAttack #TheGuardian #HeartAttackSurvivors #Implantable #Cardiologists #Electrophysiologists

avertix.com

Download the transcript here

Jason Bock, Co-Founder and CEO of CTMC, and Dr. Chris Flowers, Division Head of Cancer Medicine and Chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, are collaborating to accelerate the development of cancer cell therapies and manufacturing innovative cell therapies for cancer patients. CTMC is a joint venture between MD Anderson Cancer Center and National Resilience created to address the challenges of delivering autologous cell therapies at a scalable level. Jason and Chris highlight the value of face-to-face interaction in solving the complex logistics of getting a drug from the research into the clinic.

Jason explains, "We created CTMC to address the challenges of delivering autologous cell therapies to treat cancer patients. This modality is unique in that the starting material for each batch of product comes from the patient. And so, the actual manufacturing supply chain starts with the patient. We bring that into the manufacturing facility, engineer the cells, expand them, and then reinfuse those to the same patient. The clinic and manufacturing site relationship is much more connected than any other therapeutic modality. MD Anderson, being a leader in cancer cell therapy and seeing that cell therapy would be transformative for cancer treatment, we created this venture to address better the challenge of the connectedness between cell therapy, clinical trials, and manufacturing sites."

Chris elaborates, "Our group at MD Anderson had a very similar concept and idea that started a little bit later, about five years after that and looking at the same target. Throughout the last three years, our group has collaborated with CTMC and has taken the concept of that target and moved it from animal models and cell models where we were testing to see whether this was a good target and effective of killing lymphoma cells. We took this to animal models, where we tested and showed that it was effective. Then, collaborating with CTMC to go through the entire FDA regulatory process to get an IND approval to develop the manufacturing process. So, not just a targeted cell therapy that was effective in the lab, but a targeted cell therapy that could be effective and be administered to patients. That whole scale-up and manufacturing process was a collaboration that happen with CTMC."

#CTMC #MDAnderson #CellTherapy #ClinicalTrials #EndCancer #BiopharmaceuticalManufacturing

ctmc.com mdanderson.org

Listen to the podcast here

Jason Bock, Co-Founder and CEO of CTMC, and Dr. Chris Flowers, Division Head of Cancer Medicine and Chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, are collaborating to accelerate the development of cancer cell therapies and manufacturing innovative cell therapies for cancer patients. CTMC is a joint venture between MD Anderson Cancer Center and National Resilience created to address the challenges of delivering autologous cell therapies at a scalable level. Jason and Chris highlight the value of face-to-face interaction in solving the complex logistics of getting a drug from the research into the clinic.

Jason explains, "We created CTMC to address the challenges of delivering autologous cell therapies to treat cancer patients. This modality is unique in that the starting material for each batch of product comes from the patient. And so, the actual manufacturing supply chain starts with the patient. We bring that into the manufacturing facility, engineer the cells, expand them, and then reinfuse those to the same patient. The clinic and manufacturing site relationship is much more connected than any other therapeutic modality. MD Anderson, being a leader in cancer cell therapy and seeing that cell therapy would be transformative for cancer treatment, we created this venture to address better the challenge of the connectedness between cell therapy, clinical trials, and manufacturing sites."

Chris elaborates, "Our group at MD Anderson had a very similar concept and idea that started a little bit later, about five years after that and looking at the same target. Throughout the last three years, our group has collaborated with CTMC and has taken the concept of that target and moved it from animal models and cell models where we were testing to see whether this was a good target and effective of killing lymphoma cells. We took this to animal models, where we tested and showed that it was effective. Then, collaborating with CTMC to go through the entire FDA regulatory process to get an IND approval to develop the manufacturing process. So, not just a targeted cell therapy that was effective in the lab, but a targeted cell therapy that could be effective and be administered to patients. That whole scale-up and manufacturing process was a collaboration that happen with CTMC."

#CTMC #MDAnderson #CellTherapy #ClinicalTrials #EndCancer #BiopharmaceuticalManufacturing

ctmc.com mdanderson.org

Download the transcript here

Jay Srinivasan, CEO of Truvian Health, is on a mission to disrupt the blood testing model by making routine testing readily available and affordable with a platform that provides appropriate information for patients and physicians. The current blood testing process involves multiple tubes of blood being drawn, transportation of the blood to a lab, and waiting days for results. Truvian aims to streamline the process by placing its platform in retail clinics and physician offices where a single tube of blood can be processed on-site with results available in minutes.

Jay explains, "Our goal is to have our platform exist wherever you go. So, it could be in a retail or a corporate clinic, it could be in your physician's office labs, it could be in retail pharmacies, it could be in an arena, it could be in a mall, in a school, in a university setting, anywhere you go."

"This platform can take one tube of blood, not multiple tubes of blood because it has integrated multiple technologies that allow us to process a single tube of blood, all the results required for an annual blood test. This blood tube does not travel anywhere because the instrument is exactly where the draw would occur, and those results are available not in days but in minutes."

"The reason this is important is that today in the world, 40% of all blood orders are not being adhered to by patients like you and me because it's friction-laden even to schedule it or to get to a blood draw site to have your blood drawn. Because of that, people don't have annual and other blood draws done when they're asked to do so. More than 50% of the population in the United States is in this category. It's true even the rest of the world is walking around with some chronic condition that could have been detected early."

#TruvianHealth #BloodTesting #TruWellness #Technology #MedTech #Diagnostics #Healthcare

truvianhealth.com

Listen to the podcast here

Jay Srinivasan, CEO of Truvian Health, is on a mission to disrupt the blood testing model by making routine testing readily available and affordable with a platform that provides appropriate information for patients and physicians. The current blood testing process involves multiple tubes of blood being drawn, transportation of the blood to a lab, and waiting days for results. Truvian aims to streamline the process by placing its platform in retail clinics and physician offices where a single tube of blood can be processed on-site with results available in minutes.

Jay explains, "Our goal is to have our platform exist wherever you go. So, it could be in a retail or a corporate clinic, it could be in your physician's office labs, it could be in retail pharmacies, it could be in an arena, it could be in a mall, in a school, in a university setting, anywhere you go."

"This platform can take one tube of blood, not multiple tubes of blood because it has integrated multiple technologies that allow us to process a single tube of blood, all the results required for an annual blood test. This blood tube does not travel anywhere because the instrument is exactly where the draw would occur, and those results are available not in days but in minutes."

"The reason this is important is that today in the world, 40% of all blood orders are not being adhered to by patients like you and me because it's friction-laden even to schedule it or to get to a blood draw site to have your blood drawn. Because of that, people don't have annual and other blood draws done when they're asked to do so. More than 50% of the population in the United States is in this category. It's true even the rest of the world is walking around with some chronic condition that could have been detected early."

#TruvianHealth #BloodTesting #TruWellness #Technology #MedTech #Diagnostics #Healthcare

truvianhealth.com

Download the transcript here

Omri Shor, Co-Founder and CEO of Medisafe is driven to help patients manage their medications. Omri emphasizes that medication adherence is influenced by various factors, including access to healthcare providers, ability to refill prescriptions, side effects, and cost. Medisafe tools support patients by providing reminders, tracking medication intake, and managing drug-to-drug interactions. Partners include drug manufacturers and pharma companies that want to support patients to improve outcomes.

Omri explains, "People think medication management is one problem, but it is not. There are so many drivers and challenges behind it, and it is very personalized to the individual on one end. It's also aligned with the specific condition and the specific drug. There is no clear answer to who's more prone."

"In many cases, what we want to see is actually connected to outcomes. So, if the patient takes a medication to get to a specific outcome, they can track those outcomes in Medisafe. There are roughly 70 or 80 trackers for blood pressure, glucose levels, SpO2, sleep, moods, etc. We will then use those trackers and allow patients to share that information with HCPs healthcare professionals, whether their pharmacist, nurse, or physician, so they can share this information with the right individuals to continue supporting them."

"We have recently concluded a study that looked at healthcare utilization. We saw patients with MS and epilepsy after starting to use Medisafe. We did a pre-post analysis and found that patients with epilepsy experienced a 36% reduction in ER visits. For patients with MS, we observed a 63% reduction in ER visits. The monetary implications were roughly between $4,500 and $6,000 in cost reduction per patient annually. So, better process management yields better outcomes, which was wonderful for us to observe at Medisafe."

#Medisafe #MedicationAdherence #HealthLiteracy #DigitalHealth #MedicationManagement #DigitalCompanion

medisafe.com

Listen to the podcast here

Omri Shor, Co-Founder and CEO of Medisafe is driven to help patients manage their medications. Omri emphasizes that medication adherence is influenced by various factors, including access to healthcare providers, ability to refill prescriptions, side effects, and cost. Medisafe tools support patients by providing reminders, tracking medication intake, and managing drug-to-drug interactions. Partners include drug manufacturers and pharma companies that want to support patients to improve outcomes.

Omri explains, "People think medication management is one problem, but it is not. There are so many drivers and challenges behind it, and it is very personalized to the individual on one end. It's also aligned with the specific condition and the specific drug. There is no clear answer to who's more prone."

"In many cases, what we want to see is actually connected to outcomes. So, if the patient takes a medication to get to a specific outcome, they can track those outcomes in Medisafe. There are roughly 70 or 80 trackers for blood pressure, glucose levels, SpO2, sleep, moods, etc. We will then use those trackers and allow patients to share that information with HCPs healthcare professionals, whether their pharmacist, nurse, or physician, so they can share this information with the right individuals to continue supporting them."

"We have recently concluded a study that looked at healthcare utilization. We saw patients with MS and epilepsy after starting to use Medisafe. We did a pre-post analysis and found that patients with epilepsy experienced a 36% reduction in ER visits. For patients with MS, we observed a 63% reduction in ER visits. The monetary implications were roughly between $4,500 and $6,000 in cost reduction per patient annually. So, better process management yields better outcomes, which was wonderful for us to observe at Medisafe."

#Medisafe #MedicationAdherence #HealthLiteracy #DigitalHealth #MedicationManagement #DigitalCompanion

medisafe.com

Download the transcript here